Salt-packagedfood-WHOtargets

Global action on sodium grinding to a halt, hope that renewed efforts by WHO will spark change

Despite strong evidence of the health benefits, a new review of strategies to reduce the sodium content of packaged foods shows there has been little progress, with many countries falling short of the new World Health Organisation sodium benchmarks.

Why is salt a problem and how do we reduce it?

Globally, high blood pressure accounts for just over ten million deaths and eating too much salt - a leading cause of high blood pressure - is responsible for almost two million deaths.

Packaged or processed foods make up three quarters of the daily salt intake in high-income countries like Australia, and they’re now increasingly consumed in lower income countries.

Reducing the amount of sodium in packaged foods is an effective and cost-effective way to reduce the burden of disease attributable to high sodium intakes.

A key approach is reformulation - the process whereby manufacturers alter the nutritional composition of foods by reducing concentrations of harmful nutrients.

Either voluntary or mandatory, it can include setting reformulation targets, signed agreements between government and industry bodies or specific manufacturers and supporting manufacturers to reformulate through workshops and meetings.

What is the WHO doing about this problem?

In its 2010 Global Status Report on Noncommunicable Diseases, the WHO recommended salt reduction as a ‘best buy’, recognising it as one of the most cost effective and feasible approaches to prevent these diseases.

In 2013, it recommended Member States reduce population salt intake by 30 percent to try and reduce premature deaths from noncommunicable diseases (NCDs) by a quarter by 2025.

A subsequent systematic review by George Institute researchers found that in 2014, 75 countries had a national sodium reduction strategy, and 61 of those were working with the food industry to reduce sodium in packaged foods. However, less than half the programs were implemented in low- and middle-income countries, where the majority of deaths from NCDs occur.

Another review assessing progress towards WHO targets found that by 2019, more than 96 countries had a national sodium reduction strategy. But no country had yet met the 2025 target of 30 percent reduction in salt intake. The authors concluded that efforts would need to be accelerated if the targets are to be met.

In May 2021, the WHO released global sodium benchmarks to guide countries in setting national sodium targets in a further effort to boost the reformulation of processed foods around the world.

The new study by the George Institute team is the first to compare national strategies to reduce sodium in processed foods against these benchmarks.

What did this review find?

The latest analysis, published in Advances in Nutrition found the number of countries with national food reformulation strategies and sodium reformulation targets hasn’t changed much since 2014.

Most countries that already had programs in place had not updated them since the previous review in 2014 and they are still predominantly in high income countries. No low-income countries were found to have reformulation programs.

Where they did exist, many countries’ reformulation strategies were less than ideal, but the WHO initiative has been designed to address the key issues, summarised below.

 

ProblemSolution

 

Strategies in most countries target just one or a limited selection of foods, which is unlikely to significantly reduce population sodium intake.

 

 

WHO benchmarks cover most packaged foods across 11 major food categories, with targets for 58 sub-categories.

 

Some countries have average targets or percentage reduction targets, which can be challenging to implement and monitor.

 

WHO benchmarks are set as maximum targets set at the lowest appropriate sodium concentration - the most practical and feasible approach.

 

 

Only one quarter had plans to incrementally lower targets over time, which helps to continually reduce sodium in packaged foods.

 

The WHO has plans to progressively lower the sodium benchmarks over time.

 

Less than half had evaluated the impact of the strategy, which keeps governments and the food industry accountable for accountable for their commitments.

 

The WHO is developing global guidance for monitoring and evaluating sodium targets.

 

Where to from here?

Although the review paints a fairly bleak picture of the current efforts to reduce population sodium consumption, with little change over time, it is hoped that the latest move by the WHO may provide the impetus for change.

The benchmarks will provide a consistent target for global food manufacturers so they don’t need to work to different targets across multiple countries. There will also be step by step guidance for countries to adapt the benchmarks to their local context, where needed.

And to better assess the impact of the benchmarks initiative, the WHO is now working on guidance for global monitoring and evaluation.

Indonesia-MoU

The George Institute and Indonesia’s Universitas Brawijaya join forces to strengthen health systems

Memorandum of Understanding

The George Institute has entered a five-year long partnership with Universitas Brawijaya, a leading university in East Java, Indonesia, to pursue the common goal of strengthening health systems and improving population health.

The Institute has signed a Memorandum of Understanding with the University through its Faculty of Medicine which provides education in the field of medicine and health and consists of schools of medicine, specialist medicine, midwifery, and pharmacy.

The association between the Institute and the University isn’t new. A consortium of researchers from The George and the University have partnered with the health authorities of Malang district in East Java since 2016 on a series of projects to strengthen primary health care. The flagship program in this partnership to-date is SMARThealth.

SMARThealth program

SMARThealth is a technology-enabled clinical decision support system (CDSS) developed by The George Institute that allows community-based health workers to assess risk of a range of conditions using basic equipment and refer those at high risk to nurses or physicians for further consultation. SMARThealth has been adapted for context and implemented in community settings across Australia, India and Thailand. In Indonesia, the SMARThealth program focuses on the prevention and management of cardiovascular diseases (CVD).

“The SMARThealth program showed remarkable results in Indonesia. It was effective in improving the use of CVD preventive drugs, and in lowering blood pressure levels among people at high CVD risk in earlier studies,” says Dr D. Praveen, who led the SMARThealth project in the country.

In 2019, the Malang district government received the best health services innovation award from the Indonesian Ministry of Health for their pioneering role in strengthening community based health care through the SMARThealth Extend Program. The SMARThealth model of care is currently being scaled up by the Malang district government to include all 390 villages over a five-year program, with The George and the University providing technical and evaluation support with funding from the National Health & Medical Research Council (NHMRC)/Global Alliance for Chronic Diseases.

Burden of cardiovascular disease

Indonesia has a population of over 270 million. Cardiovascular disease is responsible for 37% of all deaths. Stroke is the leading cause, followed by coronary heart disease, and type 2 diabetes. Facility-based primary health care services alone have limited capacity to diagnose, monitor or manage cardiovascular diseases and type 2 diabetes.

“Early community-based screening and appropriate management is crucial to reducing the incidence of cardiovascular events. Strengthening primary care to manage CVDs through existing established community health care networks is a potential way to do this effectively,” says Dr. Sujarwoto, Senior Researcher at the University of Brawijaya.

The partnership between The George Institute and the University aimed at improving health systems will lay the foundation for meaningful research to address some of these challenges. The Memorandum of Understanding covers collaboration on academic and research activities, funding applications, publications, and capacity building activities including post graduate research, supervision, and exchange/placement opportunities.

It also proposes to work together on advocacy and thought leadership activities to promote wide dissemination of research work and impact.

“We believe this collaboration has the potential for meaningful and authentic knowledge-exchange. We have already done impactful work with our colleagues in Indonesia. This partnership will set the course to take that forward, come up with innovative solutions to support and strengthen health systems and improve health outcomes on a large scale,” says Dr. Anna Palagyi, Senior Research Fellow in Health Systems at the George Institute for Global Health

e-cigarettes-1335418639-NHMRC

Impact: The George Institute’s research informs Australian govt advice on e-cigarettes

NHMRC health advice

After reviewing the current available evidence, the National Health and Medical Research Council (NHMRC) has issued new public health advice on the use of e-cigarettes in Australia. The NHMRC is Australia’s peak government medical body that funds research and helps translate research into better health outcomes.

The NHMRC’s health advice states that:

  • All e-cigarette users are exposed to chemicals and toxins that have the potential to cause harm. In addition to nicotine, more than 200 chemicals have been associated with e-liquids.
  • E-cigarettes containing nicotine are addictive; people who have never smoked and use e-cigarettes are more likely to take up tobacco smoking.
  • E-cigarettes are not proven safe and effective smoking cessation aids. There are other proven safe and effective options to help smokers quit.
  • Teenagers are more likely to try e-cigarettes if they are exposed to e-cigarettes on social media

Research impact

The George Institute is proud to have contributed to the body of evidence analysed by the NHMRC to develop this health assessment. A systematic review conducted by the Institute looked at the effect of exposure to e-cigarette advertising on people’s e-cigarette-related perceptions, attitudes, intentions, and behaviours. Commissioned by the NHMRC, this review harnessed evidence from 76 studies conducted globally and published between January 2015 and June 2021.  

The review found that exposure to e-cigarette advertising across a wide range of media was positively associated with e-cigarette use among young people. The strongest available evidence was found for adolescents exposed to advertising on social media being more likely to try e-cigarettes.

“Digital marketing, particularly through social media, is the new challenge for public health – effective regulation is complex to implement, but possible. Social media companies also need to take responsibility for harms occurring through their platforms and take appropriate action”, said Soumyadeep Bhaumik, Co-Head of the Meta-research and Evidence Synthesis Unit of the George Institute, an author who contributed to the study.

Worrying uptick in e-cigarette use in Australia

Prof Simone Pettigrew, Director of Health Promotion and Behaviour Change at The George Institute and a co-author, says the findings mirror those of the effects of exposure to tobacco and alcohol advertising.  

“Our findings are consistent with outcomes in related substance use areas and support the implementation of appropriate restrictions on e-cigarette marketing to reduce harms among young people,” she warns.

Tobacco smoking in Australia is at its lowest for decades, thanks to effective policy measures and public health messaging on its harm. But the uptake of e-cigarettes by young adults is a worrying trend. According to the 2019 National Drug Strategy Household Survey, between 2016 and 2019, the proportion of people who had ever used e-cigarettes rose from 8.8% to 11.3%, with a notable increase among youth and young adults. Nearly 64% of current smokers and 20% of people who had never smoked aged 18–24 reported having tried e-cigarettes. When first using e-cigarettes, 64.5% of youth aged 14–17 and 39% of young adults aged 18–24 were never smokers. This data strengthens health experts’ argument that people who have never smoked are more likely to take up tobacco smoking, especially young adults.

One of the strongest marketing messages for e-cigarettes has been that they help tobacco smokers quit. But the NHMRC cautions against this assumption.

“There is limited evidence on the efficacy of e-cigarettes as successful cessation tools. Research studies have found that it was more common for smokers to become dual users (using both e-cigarettes and tobacco products at the same time) than quit if they used nicotine e-cigarettes. So, if you’re looking to kick the habit, seek help and find a proven, safe aid to help you quit,” advises Prof Pettigrew.

Regulatory framework in Australia

E-cigarettes that contain nicotine currently cannot be sold freely in Australia and are regulated as prescription medicines. Those without nicotine can be sold freely to adults in Australia, except in the state of Western Australia.

There are also regulations that prohibit the advertising and sponsorship of both nicotine and non-nicotine e-cigarettes. While these laws cover most types of advertising, including print, TV, and radio, online promotion has proven harder to regulate. This is a substantial problem because 70% of e-cigarettes are bought online.

With the government taking an unequivocal stand on the potential harm posed by e-cigarettes, especially to younger populations, it is time for tighter regulation of Internet advertising and higher levels of monitoring and enforcement to address e-cigarette availability.

New standard is a ‘game changer’ that will ensure healthcare workers recognise sepsis as a medical emergency

Media release

The Australian Commission on Safety and Quality in Health Care, in partnership with The George Institute for Global Health have developed a national Sepsis Clinical Care Standard to improve the delivery of sepsis care in Australia.

hydroxychloroquine preventative medicine

‘HOPE’ for the future - Showing the way forward for clinical trials in challenging circumstances

The largest study to test hydroxychloroquine (HCQ) as a preventative medicine for COVID-19 in a low- and middle-income setting, Hydroxychloroquine Prophylaxis Evaluation (HOPE), has been published in the BMJ Open journal.  

The George Institute’s team, led by Dr Bharath Kumar, Prof Vivekanand Jha and Prof. Bala Venkatesh, directed this trial in India. The study was planned and conducted on the background of early reports during the pandemic suggesting that the use of HCQ could provide an effective preventive shield against the SARS-Cov2 infection for healthcare workers (HCWs) on the frontlines at high risk of contracting the infection.  

The easy availability, lower cost, and proven safety track record of HCQ when used for other clinical indications provided additional rationale for embarking on a clinical trial to test the effectiveness of this drug in preventing COVID-19. The trial assumed particular importance for India due to the widespread shortage of personal protective equipment for HCWs in the early stages of the pandemic and the expected delays in the commencement of vaccination. In addition, the Indian Council of Medical Research (ICMR) at that point recommended the use of HCQ as a prophylactic while advocating for clinical trials.  

HOPE involved dividing the screened participants (healthcare frontline workers who were treating COVID-19 patients in hospitals, clinics, etc.) in two groups. One of the groups received HCQ in doses recommended by the Indian Medical Research Council – 800 mg on the first day followed by 400 mg each week for next 12 weeks. The follow-up went for 6 months, making this the longest follow-up duration among hydroxychloroquine-related trials. 

The trial, however, had to be halted early for futility as vaccine rollout in India began (for health care workers could take the vaccine for protection) and due to the adverse publicity surrounding the use of this drug. Considering the unstated implications and efficacy of HCQ, the ICMR raised a warning against its excessive use by healthcare workers as a preventative medicine for COVID-19 and issued an advisory towards the same. The researchers were unable to make any definitive conclusions because they could not exclude either harmful or beneficial effects of the drug.  

Despite the premature stop for futility, the trial yielded several positive dividends. It demonstrated how multicentric academic clinical research could be undertaken in the midst of a once-in-a-lifetime pandemic and crucially, created important clinical trial capacity at participating centres. Additionally, there were regulatory, operational, and funding barriers to overcome. The study investigators summarised these issues in a comment article - "Challenges in operationalising clinical trials in India during the COVID-19 pandemic" - published in the Lancet Global Health and presented solutions that would facilitate the conduct of clinical trials in a situation like the pandemic. 

"It is noteworthy that HOPE was designed and conducted with the highest standards even during one of the worst pandemics we have ever seen. The fact that we were able to enrol over 400 participants during the peak pandemic times speaks volumes about the effort which underwent." says Prof Vivekanand Jha, the Executive Director of The George Institute, India. 

The team focused on compliance with the intervention, data quality, and participant safety and was even able to achieve a 99% follow-up response rate.  

It has paved the way for further collaborative efforts and underscored the importance of timely research, fostered future research, and set the stage for many more trials in challenging times.  

“Bringing nine centres across India together to collaborate and create research capacity is evidence of our ability to bring sustainable positive change under challenging circumstances." emphasises the lead author of the study Dr Bharath Kumar, Intensivist at Apollo Hospital, Chennai & Honorary Fellow, The George Institute, India 

The George Institute for Global Health acted as a Sponsor and coordinating centre and facilitated the conduct of the HOPE trial in India. The results of the trial are consistent with previously published data from other settings. It was published by The BMJ open, and the full paper can be accessed here.